In conclusion, our results in ENZ-resistant CRPC cell models suggest that combination treatment with AKT and MEK inhibition may be a rational combination in a subset of resistant prostate cancer cases needing further investigation. The gene discussed is MAP2K7; the disease is prostate cancer.